title: Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
abstract: OBJECTIVE
  To describe the 12-month evolution of lipid profile in HIV-infected virologically suppressed patients substituting tenofovir for stavudine.
  
  
  METHODS
  'Recover' was a prospective, multicenter, switch study conducted at 120 HIV units across Spain designed to identify single nucleoside analogue substitution due to adverse events in real practice. Tenofovir substituted stavudine in 873 adult patients. No other substitutions were allowed. This lipid sub-study included 352 randomly recruited patients with complete follow-up and lipid parameters.
  
  
  METHODS
  Changes in fasting levels of total cholesterol (TC), high and low-density lipoprotein cholesterol (HDL-C and LDL-C), and triglycerides (TG) at 48 weeks, and their cardiovascular risk (CVR) translation.
  
  
  RESULTS
  At 48 weeks, there was a sustained reduction in median TC (-17.5 mg/dl; P < 0.001), LDL-C (-8.1 mg/dl; P < 0.001), and TG (-35 mg/dl; P < 0.001). HDL-C remained roughly unchanged (-0.8 mg/dl). Patients with baseline hyperlipidaemia showed greater reductions in LDL-C (-29 mg/dl; P < 0.001) and TG (-76 mg/dl; P < 0.001). The greatest TG reduction was observed in patients with severe hyper-TG (-266 mg/dl; P < 0.001). The estimated 10-year CVR decreased in all patients (P < 0.001), and to a higher extent in patients with baseline hyperlipidaemia. There was a trend towards reduction according to the use of lipid-lowering agents (11.6% to 9,9%; P = non-significant).
  
  
  CONCLUSIONS
  The substitution of tenofovir for stavudine causes a sustained improvement of dyslipidaemia. The reduction, although modest, is robust and sustained over time, and significantly reduces the CVR. This switch strategy is safe and contributes to an improvement in the lipid profile, especially TG, in HAART-treated patients.
authors.affiliation: Internal Medicine Department, Hospital de Calella, Barcelona, Spain. jmllibre@salutms.org
authors.forename: Josep M
authors.initials: JM
authors.lastname: Llibre
authors.forename: Pere
authors.initials: P
authors.lastname: Domingo
authors.forename: Rosario
authors.initials: R
authors.lastname: Palacios
authors.forename: Jesús
authors.initials: J
authors.lastname: Santos
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Pérez-Elías
authors.forename: Rainel
authors.initials: R
authors.lastname: Sánchez-de la Rosa
authors.forename: Celia
authors.initials: C
authors.lastname: Miralles
authors.forename: Antonio
authors.initials: A
authors.lastname: Antela
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D011446:Prospective Studies; D012307:Risk Factors; D018119:Stavudine / Q000009:adverse effects*; D000068698:Tenofovir
chemical_list: D019380:Anti-HIV Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D063065:Organophosphonates; D002784:Cholesterol; D000068698:Tenofovir; D018119:Stavudine; D000225:Adenine